Immupharma Share News (IMM)

ImmuPharma completes patient recruitment in Lupuzor trial

(ShareCast News) - Specialist drug discovery and development company ImmuPharma confirmed on Thursday that patient recruitment had successfully been completed, on target, within the its pivotal Phase III clinical trial of Lupuzor. The AIM-traded firm described Lupuzor as its lead programme for the p

ImmuPharma Says Paper Detailing IPP-204106 Mechanism Published

ImmuPharma makes positive progress in Lupuzor trials

(ShareCast News) - Specialist drug discovery and development company ImmuPharma updated the market on the progress of its Phase III clinical trial of Lupuzor - its lead programme for the potential breakthrough compound for Lupus - on Wednesday. The AIM-traded firm said it now had a total of 11 sites

ImmuPharma Makes Progress With Lupuzor Phase III Trial

ImmuPharma Begins Dosing Of European Patients In Lupuzor Trial

AGM, EGM Calendar - Week Ahead

ImmuPharma 2015 Loss Widens As It Focuses On Lupuzor Development

Earnings, Trading Statements Calendar - Week Ahead

ImmuPharma Begins Patient Recruitment In Europe For Lupuzor Trial

ImmuPharma doses first patients in the US

(ShareCast News) - ImmuPharma's clinical expansion into the US reached a significant point on Monday, with the first dosing of patients in its Phase III trial of the in-development lupus treatment Lupuzor. The AIM-traded drug discovery and development company confirmed in a statement that dosing had

ImmuPharma Hopeful As US Patients Begin Dosing In Lupus Clinical Trial

ImmuPharma to raise £7.5m for 'blockbuster' drug

(ShareCast News) - The 'blockbuster' potential of a drug in development saw ImmuPharma proposing a £7.5m fund raise on Friday. The AIM-traded specialist drug discovery and development company said the deal included a proposed conditional non-preemptive placing of no less than 11,824,877 Placing Shar

WINNERS & LOSERS SUMMARY: Just Eat Leaps As It Gobbles Up Takeaways

ImmuPharma Looks To Raise Minimum GBP7.5 Million In Equity (ALLISS)

ImmuPharma Says US Sites Open For Lupuzor Phase III Trial Recruitment